2013

Almirall reorganizes in Europe, cuts 250 positions

Friday, December 6, 2013

Pharmaceutical company Almirall has reorganized in Europe to optimize its portfolio potential. Pharmaceutical markets in Europe, particularly in Spain, have been affected in recent years by economically driven decisions made by various countries’ health authorities that have negatively affected the growth of those markets and the introduction and uptake of new products. 

[Read More]

GSK launches global consortium with six cancer research centers

Friday, December 6, 2013

GlaxoSmithKline has formed the Oncology Clinical and Translational Consortium (OCTC), a collaborative scientific research network comprised of six international cancer centers. The centers include Gustave Roussy (Villejuif, France), University of TexasMD Anderson Cancer Center (Houston), Memorial Sloan-Kettering Cancer Center (New York), Netherlands Cancer Institute, Princess Margaret Cancer Center, University Health Network (Toronto, Canada) and Vall d’Hebron Institute of Oncology-VHIO (Barcelona, Spain). 

[Read More]

Lexicon completes phase II study of LX1033

Thursday, December 5, 2013

Lexicon Pharmaceuticals has announced top-line results from an initial phase II study exploring the use of LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d). LX1033 is an investigational drug that inhibits serotonin synthesis in the gastrointestinal tract. Serotonin is a neurotransmitter that has been shown to play a role in the symptoms of irritable bowel syndrome.

[Read More]

Aptuit names Jonathan Goldman as CEO

Thursday, December 5, 2013

Aptuit has appointed Jonathan Goldman, M.D., as CEO. Goldman will focus on the growth of Aptuit as a provider of outsourced services in the early development space by establishing new partnerships with clients and pursuing strategic acquisitions. He joins the company after success at Icon Clinical Research, a global CRO specializing in the provision of clinical and other solutions that support phase I-IV clinical studies.

[Read More]

goBalto names Sujay Jadhav CEO

Wednesday, December 4, 2013

goBalto, a developer of next-generation solutions that simplify how clinical trials are started, has appointed Sujay Jadhav CEO. Jae Chung, former CEO and founder, will manage corporate strategy, sales and business development as president.

[Read More]